

## TRUSELTIQ PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the cardholder portion, and have the prescribing physician complete the physician portion and submit this completed form.

Date:	Provider Information (required) Provider Name:					
Patient Name:			Specialty: NPI:			
		☐ Female	Office Phone:			·
	Sex:  Male	Telliale				
Street Address:	Office Street Address:					
City:	State:	Zip:	City:	State	e:	Zip:
Patient ID: R			Physician Signature:			
	I	PHYSICIAN (	COMPLETES			
**Cł			(infigratinib) which medication is parted in its entirety for p	_	penefit	
Is this request for brand or gen		Generic		<del></del>		
1						
What is the patient's total dail:	y dose (mg/day)?	total d	aily dose (mg/day)			
<ol> <li>What is the patient's diagnod □Cholangiocarcinoma         <ul> <li>a. Does the patient hav</li> <li>□Other diagnosis (please sp</li> </ul> </li> <li>Does the prescriber agree to therapy as clinically indica</li> <li>FEMALE Patient: Is the patient final dose? □Yes □N</li> </ol>	ve a diagnosis of unrespecify):  o monitor for hyperpheted? □Yes □No  oatient of reproductive be advised to use effe	nosphatemia and	agree to withhold Tru  Ves* □No	useltiq and init	iate phosph	nate lowering
MALE Patient: Does the patient final dose? □Yes □N	patient have a female be advised to use effe		•		and for one	e month after the
4. Has the patient been on Tru	seltiq continuously fo	or the last <b>6 mo</b> i	nths, excluding sampl	es? <b>Please sel</b> e	ect answer l	below:
□NO – this is INITIATIO	<b>ON</b> of therapy, please	answer the follo	owing questions:			
a. Does the patient hav approved test? □Ye		factor receptor	2 (FGFR2) fusion or o	other rearrange	ment, as de	tected by an FDA-
b. Will a baseline opht detachment (RPED)		ation be comple	ted and will the patien	it be monitored	l for retinal	pigment epithelial
c. Has the patient had a	at least one prior thera	apy? □Yes □	lNo			
☐ YES – this is a PA reneval. Has the patient experts b. Will the patient be result.	erienced disease progr	ression or unacce	eptable toxicity while	on Truseltiq?	□Yes □	No



## TRUSELTIQ PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests <b>securely</b> online. <b>Online</b> submissions may receive <b>instant</b> responses and do not require faxing or phone calls.  Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to <b>Caremark.com/ePA.</b>
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service.  The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed.  Please only fax the completed form once as duplicate submissions may delay processing times.

faster...
easier...
better...

CVS/caremark.
Introducing ePA! Online Prior
Authorizations in minutes through
Caremark.com/ePA. Sign up today!